Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rituximab 16Cyclophosphamide 12fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Vincristine 5Radiotherapy 5Prednisone 5Lenalidomide 5Etoposide 5Doxorubicin 5Cytarabine 5Bendamustine Hydrochloride 5fludarabine 4Whole-Body Irradiation 4Filgrastim 4tazemetostat 3Mycophenolic Acid 3Melphalan 3Carmustine 3umbralisib 2ublituximab 2sargramostim 2parsaclisib 2ofatumumab 2ibritumomab tiuxetan 2duvelisib 2Tacrolimus 2Pentostatin 2Pentetic Acid 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Follicular × obatoclax × Clear all
NCT01238146 2013-06-06

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡